Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT03377101
What this trial is testing

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor Positive+1 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Study completedNCT00068601
What this trial is testing

S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

Who this might be right for
Breast CancerInfertilityMenopausal Symptoms
SWOG Cancer Research Network 257
Not applicableStudy completedNCT01899079
What this trial is testing

A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 217
Testing effectiveness (Phase 2)Study completedNCT03747042
What this trial is testing

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

Who this might be right for
Breast Cancer Female
University of Texas Southwestern Medical Center 61
Testing effectiveness (Phase 2)Study completedNCT01176669
What this trial is testing

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
Fudan University 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04567420
What this trial is testing

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Who this might be right for
Breast Cancer
Criterium, Inc. 70
Early research (Phase 1)Study completedNCT02248090
What this trial is testing

AZD9496 First Time in Patients Ascending Dose Study

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 45
Testing effectiveness (Phase 2)Study completedNCT00632723
What this trial is testing

IRESSA™ (Gefitinib) in Breast Cancer Patients

Who this might be right for
Breast Cancer
AstraZeneca 54
Testing effectiveness (Phase 2)Study completedNCT02871791
What this trial is testing

Palbociclib With Everolimus + Exemestane In BC

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor (HR)-Positive Breast Cancer
Dana-Farber Cancer Institute 41
Not applicableWithdrawnNCT01159236
What this trial is testing

Molecular Triaging of Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Not applicableStudy completedNCT00918892
What this trial is testing

Assessment of Candidate Protein Expression in Breast Cancer Specimens

Who this might be right for
Breast Cancer
Case Comprehensive Cancer Center 460
Testing effectiveness (Phase 2)Study completedNCT02028364
What this trial is testing

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Who this might be right for
Breast Cancer
Jules Bordet Institute 55
Testing effectiveness (Phase 2)Looking for participantsNCT05868226
What this trial is testing

PRE-ISPY Phase I/II Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more
QuantumLeap Healthcare Collaborative 280
Large-scale testing (Phase 3)Active Not RecruitingNCT06637150
What this trial is testing

Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 1,388
Testing effectiveness (Phase 2)Study completedNCT00313170
What this trial is testing

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer
AstraZeneca 144
Large-scale testing (Phase 3)Study completedNCT01547741
What this trial is testing

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
NSABP Foundation Inc 4,242
Testing effectiveness (Phase 2)Study completedNCT02676986
What this trial is testing

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer

Who this might be right for
Primary Breast Cancer ER+vePrimary Breast Cancer AR+ve TNBN
Queen Mary University of London 221
Post-approval studies (Phase 4)UnknownNCT02089854
What this trial is testing

Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer

Who this might be right for
Female Breast Cancer
Peking Union Medical College Hospital 800
Large-scale testing (Phase 3)Study completedNCT00288002
What this trial is testing

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Who this might be right for
Breast Cancer
GBG Forschungs GmbH 1,500
Not applicableStudy completedNCT01463007
What this trial is testing

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

Who this might be right for
Breast Cancer
Jaroslaw Hepel 40
Next Page